Rozycki Sarah K, Nguyen Vylan, Miroballi Natalia, Rutledge Emily C, Balk Ethan M, Antosh Danielle D
Division of Urogynecology, Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, TX.
College of Medicine, Texas A&M University, Houston, TX.
Am J Obstet Gynecol. 2025 May;232(5):422-431.e4. doi: 10.1016/j.ajog.2024.12.031. Epub 2025 Jan 7.
This study aimed to compare the rates of surgical site infection after hysterectomy using vaginal antisepsis with chlorhexidine gluconate vs povidone-iodine.
PubMed, Embase, and ClinicalTrials.gov databases were queried from January 1, 1985 through December 7, 2023.
Randomized controlled trials and nonrandomized comparisons of interventions of chlorhexidine gluconate and povidone-iodine vaginal antiseptic preparation before hysterectomy were included. The primary outcome was surgical site infection as defined by the Centers for Disease Control and Prevention. Secondary outcomes included postoperative urinary tract infections and vaginal culture specimens. Large single-group studies of vaginal chlorhexidine gluconate reporting adverse events and case reports of desquamation were also included.
The methodologic quality of each study was assessed using the original Cochrane RoB (Risk of Bias) and ROBINS-I (Risk of Bias in Non-Randomized Studies - of Interventions) tools. Restricted maximum likelihood meta-analyses of odds ratios were conducted.
A total of 5289 abstracts were screened; 10 met the inclusion criteria, with a total of 9618 participants. The studies included 4 randomized controlled trials (n=306), 3 prospective nonrandomized comparisons of interventions (n=1089), and 3 retrospective nonrandomized comparisons of interventions (n=8223). Povidone-iodine was compared with 4% chlorhexidine gluconate in 4 studies (n=2491), 2% chlorhexidine gluconate in 2 studies (n=236), 0.1% chlorhexidine gluconate in 1 study (n=50), and both 2% and 4% chlorhexidine gluconate in 1 study (n=49). Meta-analysis revealed no statistically significant difference in surgical site infections, although they were somewhat more common with chlorhexidine gluconate (summary odds ratio, 1.22; 95% confidence interval, 0.91-1.63). The relative effect of antiseptic preparations on urinary tract infections was unclear, with an imprecise summary odds ratio (1.18; 95% confidence interval, 0.65-2.12). Positive vaginal cultures were less common with chlorhexidine gluconate preparation (summary odds ratio, 0.10; 95% confidence interval, 0.04-0.27). Two studies reported no adverse events with chlorhexidine gluconate, and 2 found no difference in vaginal irritation when compared with povidone-iodine. Two case reports described vaginal desquamation or hypersensitivity with chlorhexidine gluconate.
There is no evidence of a difference in postoperative infection with chlorhexidine gluconate use compared with povidone-iodine, but chlorhexidine gluconate vaginal preparation results in lower rates of positive intraoperative vaginal cultures. Despite inadequate reporting, risk of adverse events appears low.
本研究旨在比较子宫切除术后使用葡萄糖酸氯己定与聚维酮碘进行阴道消毒后的手术部位感染率。
检索了1985年1月1日至2023年12月7日的PubMed、Embase和ClinicalTrials.gov数据库。
纳入子宫切除术前使用葡萄糖酸氯己定和聚维酮碘阴道抗菌制剂的随机对照试验及非随机对照比较。主要结局为美国疾病控制与预防中心定义的手术部位感染。次要结局包括术后尿路感染及阴道培养标本。还纳入了报告不良事件的葡萄糖酸氯己定阴道大样本单组研究及脱屑病例报告。
使用原始的Cochrane RoB(偏倚风险)和ROBINS-I(非随机干预研究中的偏倚风险)工具评估每项研究的方法学质量。进行比值比的受限最大似然荟萃分析。
共筛选5289篇摘要;10项符合纳入标准,共9618名参与者。这些研究包括4项随机对照试验(n = 306)、3项干预措施的前瞻性非随机对照比较(n = 1089)和3项干预措施的回顾性非随机对照比较(n = 8223)。4项研究(n = 2491)中比较了聚维酮碘与4%葡萄糖酸氯己定,2项研究(n = 236)中比较了聚维酮碘与2%葡萄糖酸氯己定,1项研究(n = 50)中比较了聚维酮碘与0.1%葡萄糖酸氯己定,1项研究(n = 49)中比较了聚维酮碘与2%和4%葡萄糖酸氯己定。荟萃分析显示手术部位感染无统计学显著差异,尽管葡萄糖酸氯己定组的感染似乎略多(汇总比值比,1.22;95%置信区间,0.91 - 1.63)。抗菌制剂对尿路感染的相对影响尚不清楚,汇总比值比不精确(1.18;95%置信区间,0.65 - 2.12)。葡萄糖酸氯己定制剂的阴道培养阳性结果较少见(汇总比值比,0.10;95%置信区间,0.04 - 0.27)。2项研究报告葡萄糖酸氯己定无不良事件,2项研究发现与聚维酮碘相比,阴道刺激无差异。2例病例报告描述了葡萄糖酸氯己定引起的阴道脱屑或过敏反应。
没有证据表明使用葡萄糖酸氯己定与聚维酮碘术后感染存在差异,但葡萄糖酸氯己定阴道制剂可降低术中阴道培养阳性率。尽管报告不充分,但不良事件风险似乎较低。